Search Results - "Kachuck, NJ"

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by FROHMAN, E. M, GOODIN, D. S, KACHUCK, N. J, LEVIN, M. C, PHILLIPS, J. T, RACKE, M. K, RIVERA, V. M, STUART, W. H, CALABRESI, P. A, CORBOY, J. R, COYLE, P. K, FILIPPI, M, FRANK, J. A, GALETTA, S. L, GROSSMAN, R. I, HAWKER, K

“…Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently,…”
Get full text

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis by Kachuck, Norman J

“…New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a…”
Get full text

Increased CXCL8 (IL-8) expression in Multiple Sclerosis by Lund, Brett T., Ashikian, Nazely, Ta, Huy Q., Chakryan, Yervand, Manoukian, Krikor, Groshen, Susan, Gilmore, Wendy, Cheema, Gurtej S., Stohl, William, Burnett, Margaret E., Ko, David, Kachuck, Norman J., Weiner, Leslie P.

“…Multiple Sclerosis (MS) is a chronic inflammatory disease of the CNS which is characterized by large mononuclear cell infiltration and significant…”
Get full text

Immunological aspects of secondary progressive multiple sclerosis by Weiner, LP, Kachuck, NJ, Gilmore, W., Lund, B.

Get full text

The utility of MRI in suspected MS: report of the Therapeutics and technology assessment Subcommittee of the American Academy of Neurology by Frohman, EM, Goodin, DS, Calabresi, PA, Corboy, JR, Coyle, PK, Filippi, M, Frank, JA, Galetta, SL, Grossman, RI, Hawker, K, Kachuck, NJ, Levin, MC, Phillips, JT, Racke, MK, Rivera, VM, Stuart, WH

“…[...]the presence of two or more gadolinium (Gd)-enhancing lesions at baseline and the appearance of either new T2 lesions or new Gd enhancement on follow-up…”
Get full text

Immunological aspects of secondary progressive multiple sclerosis by Weiner, L P, Kachuck, N J, Gilmore, W, Lund, B

Get full text